Tina Liu, M.B.A., Entrepreneur In Residence, Wyss Institute; CEO, Ally Therapeutics Together with a scientific team led by geneticist George Church and immunologist Ying Kai Chan, Tina is spinning out Ally Therapeutics from the Wyss Institute at Harvard. Ally seeks to systematically solve the immune response issues that limit gene therapies today. Prior, Tina was a private equity investor at TPG Capital, where she evaluated potential investments $1Bn+ in size across commercial pharma and other sectors of the healthcare industry. Before that, Tina was an investment banker at Morgan Stanley, where she advised healthcare companies on key transactions including mergers and acquisitions, equity and debt financings, and other strategic alternatives. Tina received her MBA with Distinction from Harvard Business School and her BA, magna cum laude, from Harvard College.